Feature | January 14, 2014

Boston Scientific Invests in Bioresorbable Stent Startup Amaranth Medical

cath lab stents bioresorbable amaranth fortitude scaffold
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The additional investment capital will be used to advance the clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE marking. In addition, the funding will support continued development of the next-generation Fortitude bioresorbable scaffold, which will have thinner struts than any currently available polymeric bioresorbable scaffold.
 
"The properties of the proprietary polymer and the unique manufacturing processes that we developed have allowed us to produce a scaffold with mechanical strength and durability which we believe exceeds that of all currently available bioresorbable scaffolds,” said Kamal Ramzipoor, CEO, Amaranth.
 
The non-drug-eluting Fortitude scaffold was previously evaluated in a study of 13 patients with symptomatic coronary artery disease (CAD), results of which were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 27, 2013. The data suggested that the Fortitude scaffold maintained its mechanical integrity, with late lumen loss comparable to that observed with bare metal stents
 
The scaffold is designed to afford the strength of metal stents to assist the artery during the remodeling process following an interventional procedure, without leaving behind a permanent implant with inherent clinical limitations.
 
In 2014, Amaranth will begin enrolling a second cohort of patients to evaluate a drug-eluting Fortitude scaffold.
 
For more information: www.amaranthmedical.com

Related Content

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients
News | Heart Failure| May 26, 2017
Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab| May 23, 2017
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures, SCAI, Corindus CorPath 200
News | Robotic Systems| May 16, 2017
The largest real-world study of robotic percutaneous coronary intervention (PCI) demonstrated clinical and technical...
Adept Medical Launches IR Platform, interventional radiology
Technology | Cath Lab| May 16, 2017
Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and...
Overlay Init